Khatri, Manisha published the artcileNitazoxanide/Camostat combination for coronavirus disease 2019 (COVID-19): an unexplored potential therapy, Recommanded Product: 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, the main research area is coronavirus disease 2019 nitazoxanide camostat.
Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lies behind the ongoing outbreak of coronavirus disease 2019 (COVID-19) and its ripple effects has brought major challenges to worldwide health systems. Urgent strategies are required to manage this pandemic and repurposing of existing drugs offer an option forward. A combination drug therapy for COVID-19 aims to prevent both the virus entry/spread as well as quelling the immune system havocs that the virus wreaks in the human body. This article analyzes Nitazoxanide/Camostat combination for their potential activity against SARS-CoV-2. Nitazoxanide, FDA approved drug potentiates host antiviral response, thereby reducing viral replication, titer and ensuing immune dysregulation. Camostat, a potent serine protease inhibitor locks viral cell entry along with the potential to decrease COVID-19-associated hypercoagulability. Both the drugs do not inhibit CYP 450 enzymes and could be co-administered. Based on the combined pathophysiol. and pharmacol. potential, the drugs combination can prospectively be recommended for early evaluation with possible clin. trials of this combination.
Chemical Biology Letters published new progress about Antiviral agents. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Recommanded Product: 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics